Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11163)	11/15/1997 4:11:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

>> If Pfizer makes sales of droloxifene for any indication other than breast cancer, including osteoporosis, the royalty will then be 3% for all indications.<< Does this mean that then the 1% royalty rate for the breast cancer indication will jump to 3%? It is interesting that the 3 new negative posters we have here on the thread all come from threads where you have gone to attempt to help educate others. Obviously there are those who resent being educated and as one of them says, have decided to come here and educate you in return. Too bad they know nothing about biotechs or LGND. Things have improved some since the early years of the Scientific Revolution, however. There were many who wanted to burn Copernicus for suggesting that the earth revolved around the sun. Their modern day counterparts are only threatening you with the SEC. Maybe things haven't really changed that much (:>)